Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer - ER+, HER2 -”

607 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 607 results

Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559
What this trial is testing

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 189
Testing effectiveness (Phase 2)Looking for participantsNCT06000917
What this trial is testing

Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Who this might be right for
Breast CancerNeoadjuvant
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 62
Early research (Phase 1)Active Not RecruitingNCT05509790
What this trial is testing

LY3484356 in Chinese Participants With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 17
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Testing effectiveness (Phase 2)Looking for participantsNCT07159451
What this trial is testing

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 140
Testing effectiveness (Phase 2)Ended earlyNCT00517361
What this trial is testing

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University of Chicago 11
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Not applicableStudy completedNCT03981705
What this trial is testing

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Who this might be right for
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
Masonic Cancer Center, University of Minnesota 8
Large-scale testing (Phase 3)UnknownNCT04753177
What this trial is testing

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Who this might be right for
The Neoadjuvant Therapy
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287098
What this trial is testing

Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 600
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Large-scale testing (Phase 3)UnknownNCT03507465
What this trial is testing

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 290
Large-scale testing (Phase 3)Not Yet RecruitingNCT07005557
What this trial is testing

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdjuvant Therapy
Fudan University 1,244
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Not applicableEnded earlyNCT03619044
What this trial is testing

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Who this might be right for
HER2-positive Breast Cancer
Institut Claudius Regaud 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Not applicableLooking for participantsNCT06127979
What this trial is testing

Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 42
Load More Results